[1]李秀秀,张玉佩,许春玲,等.基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点[J].陕西中医,2024,(6):798-802.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
　LI Xiuxiu,ZHANG Yupei,XU Chunling,et al.Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism[J].,2024,(6):798-802.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.016]
点击复制

基于胆汁酸-肠道菌群对话机制探讨非酒精性脂肪性肝病肝郁脾虚病机特点
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年6期
页码:
798-802
栏目:
学术探讨
出版日期:
2024-06-05

文章信息/Info

Title:
Exploration of the pathogenic characteristics of non-alcoholic fatty liver disease with liver depression and spleen deficiency based on the bile acid-gut microbiota dialogue mechanism
作者:
李秀秀1; 张玉佩2; 许春玲3; 王宇晖3; 闫海震3
(1.暨南大学附属第一医院,广东 广州 510632; 2.暨南大学中医学院,广东 广州 510632; 3.暨南大学附属广州红十字会医院,广东 广州 510235)
Author(s):
LI Xiuxiu; ZHANG Yupei; XU Chunling; WANG Yuhui; YAN Haizhen
(The First Affiliated Hospital of Jinan University,Guangzhou 510632,China)
关键词:
非酒精性脂肪性肝病;  肠道菌群;  胆汁酸;  肝郁脾虚;  代谢紊乱;  分子机制
Keywords:
Non-alcoholic fatty liver disease;  Gut microbiota;  Bile acids;  Liver depression and spleen deficiency;  Metabolic disorder;  Molecular mechanism
分类号:
R 575.5
DOI:
DOI:10.3969/j.issn.1000-7369.2024.06.016
文献标志码:
A
摘要:
胆汁酸与肠道菌群关系失衡与非酒精性脂肪性肝病密切相关。基于中医理论及临床研究,发现“肝郁脾虚”是非酒精脂性肪性肝病发病过程中的关键病机。结合现代医学及分子生物学研究,认为肠道菌群紊乱与中医“脾虚”密切相关,胆汁酸分泌异常为“肝郁”的微观体现,而且在非酒精性脂肪性肝病发展进程中,“胆汁酸与肠道菌群失衡”与中医“肝郁脾虚”的基本病机相契合。因此,从“胆汁酸与肠道菌群失衡”角度探讨非酒精性脂肪性肝病“肝郁脾虚”的现代生物学内涵,研究“肝郁脾虚”的病机实质及其代表方药,有望为非酒精性脂肪性肝病的防治提供更有效的方法和策略。
Abstract:
The imbalance of bile acids and gut microbiota is closely related to non-alcoholic fatty liver disease(NAFLD).Based on traditional Chinese medicine theory and clinical research, it has been found that “liver depression and spleen deficiency” is the key pathogenesis in the development of NAFLD.Combined with modern medicine and molecular biology research, it is believed that the disruption of gut microbiota is closely related to “spleen deficiency” in traditional Chinese medicine, and the abnormal secretion of bile acids reflects the microscopic manifestation of “liver depression”.Furthermore, in the progression of NAFLD, the imbalance of bile acids and gut microbiota aligns with the fundamental pathogenesis of “liver depression and spleen deficiency” in traditional Chinese medicine.Therefore, exploring the biological implications of “liver depression and spleen deficiency” in NAFLD from the perspective of “imbalance of bile acids and gut microbiota” may provide more effective methods and strategies for the prevention and treatment of NAFLD, as well as shed light on the essential pathogenesis and representative herbal formulas related to “liver depression and spleen deficiency”.

参考文献/References:

[1] HUANG D Q,SERAG H B, LOOMBA R.Global epidemiology of NAFLD-related HCC:Trends,predictions,risk factors and prevention[J].Nature Reviews Gastroenterology & Hepatology,2021,18(4):223-238.
[2] RIAZI K,AZHARI H,CHARETTE J H,et al.The prevalence and incidence of NAFLD worldwide:A systematic review and meta-analysis[J].The Lancet Gastroenterology & Hepatology,2022,7(9):851-861.
[3] ZHOU J,ZHOU F,WANG W,et al.Epidemiological features of NAFLD from 1999 to 2018 in China[J].Hepatology,2020,71(5):1851-1864.
[4] MAHMOUDIAN D S,BHATTACHARYYA S,BRYDGES C R,et al.Gut microbiome-linked metabolites in the pathobiology of major depression with or without anxiety:A role for bile acids[J].Frontiers in Neuroscience,2022,16:937906.
[5] SEN P,QADRI S,LUUKKONEN P K,et al.Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease[J].Journal of Hepatology,2022,76(2):283-293.
[6] GILLARD J,LECLERCQ I A.Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease[J].Clinical Science,2023,137(1):65-85.
[7] 石艳红,邵英.生物钟相关基因CLOCK及褪黑素受体MT1和MT2基因与2型糖尿病患者肠道菌群及炎症因子相关性分析[J].陕西医学杂志,2023,52(3):335-339.
[8] SHEN F,ZHENG R D,SUN X Q,et al.Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease[J].Hepatobiliary & Pancreatic Diseases International,2017,16(4):375-381.
[9] SCHWIMMER J B,JOHNSON J S,ANGELES J E,et al.Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease[J].Gastroenterology,2019,157(4):1109-1122.
[10] LOOMBA R,SEGURITAN V,LI W,et al.Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease[J].Cell Metabolism,2017,25(5):1054-1062.
[11] PONZIANI F R,BHOORI S,CASTELLI C,et al.Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J].Hepatology,2019,69(1):107-120.
[12] JASIRWAN C,MURADI A,HASAN I,et al.Correlation of gut firmicutes/bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease[J].Bioscience of Microbiota,Food and Health,2021,40(1):50-58.
[13] DELIK A,DINCER S,ULGER Y,et al.Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease[J].Gene,2022,833(30):146587.
[14] 刘应莉,王艳荣,张秋瓒.肠道菌群-过氧化物酶体增殖物激活受体信号通路及其在代谢相关脂肪性肝病发病中的作用研究进展[J].陕西医学杂志,2021,50(9):1166-1169.
[15] CHIANG J Y,FERRELL J M.Discovery of farnesoid X receptor and its role in bile acid metabolism[J].Molecular and Cellular Endocrinology,2022,548(15):111618.
[16] COLLINS S L,STINE J G,BISANZ J E,et al.Bile acids and the gut microbiota:Metabolic interactions and impacts on disease[J].Nature Reviews Microbiology,2023,21(4):236-247.
[17] ADAMS L A,WANG Z,LIDDLE C,et al.Bile acids associate with specific gut microbiota,low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease[J].Liver International,2020,40(6):1356-1365.
[18] ARON W J,VIGLIOTTI C,WITJES J,et al.Gut microbiota and human NAFLD:Disentangling microbial signatures from metabolic disorders[J].Nature Reviews Gastroenterology & Hepatology,2020,17(5):279-297.
[19] SMIRNOVA E,MUTHIAH M D,NARAYAN N,et al.Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD[J].Hepatology,2022,76(6):1811-1824.
[20] MATSUI M,FUKUNISHI S,NAKANO T,et al.Ileal bile acid transporter inhibitor improves hepatic steatosis by ameliorating gut microbiota dysbiosis in NAFLD model mice[J].Mbio,2021,12(4):1155-1121.
[21] JIAO N,LOOMBA R,YANG Z H,et al.Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD[J].Physiological Genomics,2021,53(8):336-348.
[22] GU Y,ZHANG W,HU Y,et al.Association between nonalcoholic fatty liver disease and depression:A systematic review and meta-analysis of observational studies[J].Journal of Affective Disorders,2022,301(15):8-13.
[23] SHEA S,LIONIS C,KITE C,et al.Non-alcoholic fatty liver disease(NAFLD)and potential links to depression,anxiety,and chronic stress[J].Biomedicines,2021,9(11):1697.
[24] 谢维宁,彭红兵,李烨,等.柴胡疏肝散对肝郁脾虚型非酒精性脂肪肝患者的临床疗效及肠道菌群的影响[J].中国实验方剂学杂志,2021,7(3):129-137.
[25] 宋丽,石蕊,赵香君.手足十二针联合加味茵陈蒿汤治疗非酒精性脂肪肝及对患者肠道菌群的影响[J].陕西中医,2022,43(2):252-256.
[26] 何珂,陆西宛,朱丽华,等.脾虚湿困型肥胖症患者肠道菌群分布多样性及相关性研究[J].中国中西医结合杂志,2022,42(1):40-48.
[27] 何晗,但林蔚,王巧珍,等.基于16S rRNA高通量测序研究麸炒前后白术水煎液及多糖对脾虚泄泻型大鼠肠道菌群的影响[J].中药药理与临床,2022,38(2):136-141.
[28] 闫蕴孜,孙凌云,闫韶花,等.基于中医脾虚量表的结直肠癌患者临床特征,肠道菌群及免疫功能相关性研究[J].中国中医基础医学杂志,2022,28(3):405-411.
[29] 王淼蕾,刘俊宏,汪龙德,等.疏肝健脾法对肝郁脾虚型IBS-D大鼠肠黏膜屏障功能的影响[J].时珍国医国药,2022,33(1):29-33.
[30] 杜青,李心亮,曾宏亮,等.理中丸对脾虚型腹泻大鼠结肠黏膜屏障IL-22-MUC2/claudin-2信号通路的影响[J].中国实验动物学报,2023,31(2):217-224.
[31] 贾连群,宋囡,吕美君,等.基于“脾气散精”理论探讨肠道微生物稳态与糖脂代谢的关系[J].辽宁中医杂志,2019,30(9):1862-1864.
[32] 王钰,庞琳琳,张会永,等.基于高脂血症脾虚痰浊证肝脏甘油三酯代谢的“土侮木”的科学内涵探讨[J].时珍国医国药,2022,33(2):438-440.
[33] WANG S,SHENG F,ZOU L,et al.Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism[J].Journal of Advanced Research,2021,34:109-122.
[34] ZHANG J,WANG X,JIANG H,et al.MicroRNA-185 modulates CYP7A1 mediated cholesterol-bile acid metabolism through post-transcriptional and post-translational regulation of FoxO1[J].Atherosclerosis,2022,348:56-67.
[35] 吴皓萌,郑欢,秦书敏,等.从肠道菌群-胆汁酸代谢轴失调探讨腹泻型肠易激综合征肝郁脾虚的机制[J].中华中医药杂志,2022,37(6):3123-3127.
[36] 张星星,吴坚,裴丽霞,等.健脾疏肝法对腹泻型肠易激综合征患者疗效观察及对肠道菌群的影响[J].中国实验方剂学杂志,2019,25(13):79-86.
[37] 郑洁,董燕,梁健,等.调神健脾针刺疗法配合艾灸对肝郁脾虚证IBS-D患者中医证候积分及肠道微生态的影响[J].陕西中医,2022,43(10):1477-1480.
[38] LARABI A B,MASSON H L,BAUMLER A J.Bile acids as modulators of gut microbiota composition and function[J].Gut Microbes,2023,15(1):2172671.

相似文献/References:

[1]陆黎娟,刘 迎△,陈卫海,等.多囊卵巢综合征中医药研究进展*[J].陕西中医,2020,(3):403.
[2]俞 慧,杨 挺△,黄 伟.大黄承气汤联合保留灌肠对重症急性胰腺炎肠道菌群及免疫功能的影响*[J].陕西中医,2020,(10):1418.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.021]
　YU Hui,YANG Ting,HUANG Wei..Effect of Dahuang Chengqi decoction combined with retention enema on intestinal flora and immune function in severe acute pancreatitis[J].,2020,(6):1418.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.021]
[3]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(6):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[4]黄 进,陆雪萍.非酒精性脂肪性肝病从脾论治刍议[J].陕西中医,2021,(2):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
　HUANG Jin,LU Xueping.Analysis of treatment of nonalcoholic fatty liver disease from spleen[J].,2021,(6):225.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.022]
[5]钟方红,皮特俊章,钟 琴,等.中药对高尿酸血症患者肠道菌群影响的研究进展[J].陕西中医,2021,(2):265.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.032]
　ZHONG Fanghong,PI Tejunzhang,ZHONG Qin,et al.Research progress of the effect of traditional Chinese medicine on intestinal flora of patients with hyperuricemia[J].,2021,(6):265.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.032]
[6]敬秀平,宋小平,刘 珊.加味白头翁汤灌肠治疗慢性溃疡性结肠炎临床研究[J].陕西中医,2021,(8):1060.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.018]
　JING Xiuping,SONG Xiaoping,LIU Shan.Study on the therapeutic effect and inflammatory mechanism of enema with modified Baitouweng decoction in the treatment of chronic ulcerative colitis[J].,2021,(6):1060.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.018]
[7]何佳美,银子涵,梁繁荣.基于“心合小肠”理论探讨针灸调控肠道菌群治疗心血管疾病的可行性[J].陕西中医,2021,(11):1581.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.020]
　HE Jiamei,YIN Zihan,LIANG Fanrong.Exploration on feasibility of acupuncture and moxibustion preventing cardiovascular diseases by regulation of intestinal flora interaction based on heart and small intestine[J].,2021,(6):1581.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.020]
[8]李慧敏,李鹏辉,吉兰洁,等.连术消渴颗粒对2型糖尿病模型大鼠肠道菌群、肠黏膜屏障功能及水通道蛋白的影响[J].陕西中医,2021,(12):1663.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.002]
　LI Huimin,LI Penghui,JI Lanjie,et al.Effect of Lianzhu Xiaoke granule on intestinal flora,intestinal mucosal barrier function and aquaporin in type 2 diabetes model rats[J].,2021,(6):1663.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.002]
[9]宋 丽,石 蕊,赵香君.手足十二针联合加味茵陈蒿汤治疗非酒精性脂肪肝及对患者肠道菌群的影响[J].陕西中医,2022,(2):252.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.027]
　SONG Li,SHI Rui,ZHAO Xiangjun.Effect of hand foot twelve needles combined with modified Yinchenhao decoction on intestinal flora of patients with nonalcoholic fatty liver disease[J].,2022,(6):252.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.027]
[10]王士萌,陈 璐,冯晓玲.肾虚血瘀型复发性流产与肠道菌群相关性研究进展[J].陕西中医,2022,(2):261.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.029]
　WANG Shimeng,CHEN Lu,FENG Xiaoling.Mechanism correlation and research progress between recurrent spontaneous abortion of kidney deficiency-blood stasis type and intestinal flora[J].,2022,(6):261.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.029]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助面上项目(82274393); 国家中医药管理局杨钦河全国名老中医药专家传承工作室建设项目[国中医药人教函(2022)75号]; 广东省中医药局科研项目(20221302,20242066); 广州市中医药和中西医结合科技项目(20212A010022)
更新日期/Last Update: 2024-06-11